BrightPath Biotherapeutics Co., Ltd.
Announcement on the Issuance of the 21st Stock Acquisition Right with Exercise Price Adjustment Provisions through Third-Party Allotment and the Conclusion of the Share Purchase Agreement for the Rights
Announces funding via third-party allotment using stock acquisition rights. 345,000 units, total 2,415,000 yen, potential shares 34,500,000 shares, initial exercise price 57 yen, adjusted to 97% of closing price on each adjustment date with rounding up; minimum 29 yen. Acquired rights, exercise suspension period, and caps on allotted shares are designed to manage dilution and enable flexible fundraising.
Key Figures
- 345,000 units: total number of stock acquisition rights
- 34,500,000 shares: target shares (100 shares per right)
- 1,952,915,000 yen: estimated net proceeds
AI要約
Overview of financing
BrightPath Bio resolved to issue the 21st stock acquisition rights through third-party allotment. Allottee is Phillip Capital Securities Inc., 345,000 units, total 2,415,000 yen, implied underlying shares 34,500,000 shares. Exercise price initially 57 yen, subsequently adjusted on each adjustment date to 97% of the market closing price with rounding up, with a lower bound of 29 yen. The design includes terms such as acquisition provisions, exercise suspension period, and fixed maximum number of issuable shares to balance dilution control with funding flexibility.
Use of funds and outlook
Funds are to be used primarily for BP2202 US Phase I clinical trial costs, new pipeline development, and other operating funds. Timing is assumed from June 2027 to September 2028. Depending on stock price trends, the amount and timing of funding may vary, and actual expenditures will be determined according to exercise status.
BrightPath Bio Inc.
Company overview · Stock price · Financial data · All IR
